Companies Urged Not To View EU Privacy Law As A Barrier To Conducting Decentralized Trials
Executive Summary
A senior regulator from the European Medicines Agency says that while the EU General Data Protection Regulation can be intellectually challenging, the law is needed, and it should not deter companies from conducting decentralized clinical trials because of concerns they might have over the use digital tools to capture and process patient and trial data.
You may also be interested in...
EU Makes Only Limited Use Of Remote Clinical Trial Monitoring
While regulators worldwide are opening up to the possibility of remote verification of source data from clinical trial sites because of COVID-19 restrictions, this approach is finding less favor in the EU, mainly because of strict data protection rules.
EMA Aligns Antibiotics Guideline To Help Facilitate Global Trials
The EU regulator says it supports a globally aligned approach to the development of new antimicrobial medicines.
Philippines Considers Regulatory Reliance To Speed Up Evaluating Trial Applications
The Philippines FDA is looking to leverage the work conducted by “stringent” regulators when it comes to reviewing certain clinical trial applications.